Clinical research section

Click to scroll back to the top

Research & Education Stories From Houston Methodist

result

Clinical Research

Complementing Treatments for Myasthenia Gravis

Complement protein 5 inhibitors have emerged as a new line of treatment for the debilitating neuromuscular disorder. Now, a clinical study at Houston Methodist is testing the drugs’ long-term efficacy and safety.

New FDA-Approved Drug Could Be the Much-Awaited Panacea for Alzheimer’s

A phase III clinical study is testing lecanemab in slowing the onset of cognitive decline.

An Ongoing Phase II Clinical Trial for Bladder Cancer

Combining Neoadjuvant Drug Sasanlimab and Stereotactic Body Radiotherapy May Improve The Quality Of Life In Muscle-Invasive Bladder Cancer Patients

Antimicrobial Resistance Research is DYNAMITE at Houston Methodist

Houston Researcher leads multi-institutional NIH P01 to tackle antimicrobial resistance termed DYNAMITE: Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

Do Motor Neurons First Die in the Brain? Study Provides Clues about ALS Origins

Transcranial rotating permanent magnet stimulation on ALS patients provides insights into the pathogenesis of the debilitating motor neuron disease.

Houston Methodist joins the Gulf Coast Consortia

Consortia is comprised of eight hospitals, medical schools and research entities in the Texas Medical Center

A New FDA-Approved Treatment for Sufferers of Chronic Constipation

A capsule designed to vibrate in the GI tract to stimulate the bowels accelerates movement in the field of chronic constipation.

Houston Methodist Conducts First-Ever Study into a Challenging Condition

Functional Defecatory Disorder study finds key differences in activation patterns of patients' brains

Can regulating cellular aging mitigate both cancer and heart disease?

Can regulating cellular aging mitigate both cancer and heart disease?

Improved options for patients with severe retinal vascular disease

In Phase III clinical trials, faricimab met noninferiority endpoints against current drug, aflibercept, to treat diabetic macular edema and neovascular age-related macular degeneration.

Innovative Treatment for Chronic Rhinitis is Safe and Effective

Takashima and his team conducted a multi-institutional trial to determine the safety and efficacy of temperature-controlled radiofrequency (RF) neurolysis of the posterior nasal nerve area for the treatment of chronic rhinitis.

Rare wrist bone fusion sighting in collegiate baseball pitcher

In a serendipitous finding, Houston Methodist orthopedic surgeons discover a rare bilateral carpal fusion in the wrist of a high-level collegiate athlete.

Masters of disguise: Glioblastomas trick the immune system by masquerading as reproductive tissue

By conducting an in-depth analysis of four glioblastoma transcriptome databases Houston Methodist researchers have found that glioblastoma expresses a variety of male- and placental-specific proteins to lure regulatory T cells into protecting rather than attacking it.

Novel drug combination can target triple-negative breast cancer for treatment

In a Phase I/II clinical trial, Houston Methodist researchers paired a conventional chemotherapy drug with a pan-nitric oxide synthase inhibitor to successfully target triple-negative breast cancers.

Houston Methodist researchers review the similarities and contrasts of amphibian regeneration and mammalian cancer from an evolutionary biology perspective

Investigators speculated that susceptibility to cancer development in adult mammals may be determined by the loss of an advanced regenerative capability during evolution.

Houston Methodist and Purdue University Make a Breakthrough That May Result in a More Effective Tuberculosis Vaccine

A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice

Houston Methodist researchers identify over 50 long-term effects of COVID-19

Lingering symptoms range from mild to debilitating and last for weeks to months after recovery

The COVID-19 virus SARS-COV-2 affects the brain and may cause long-range complications

Mounting evidence suggests that the SARS-COV-2 virus responsible for COVID-19 causes neurological complications in addition to the signature respiratory symptoms.

George and Angelina Kostas Gifts Help Houston Methodist Become Leaders in Heart and Vascular Nanotechnology Research

A generous gift from the Kostases allowed the Houston Methodist Academic Institute to begin operations at the George and Angelina Kostas Research Center for Cardiovascular Nanomedicine in 2014.

Cancer cell type (seed) and tumor microenvironment (soil) control therapeutic antibody delivery and efficacy

Primary tumor cells (seed) and metastatic organs (soil) determine complex tumor microenvironment heterogeneities- a major cause of resistance against immunotherapeutics, including immune checkpoint inhibitors important in breast cancer treatment strategies.

Semantic dementia study yields new findings

Inflammation research uncovers likely therapeutic target for neurodegenerative aphasia disorder

Poly ADP Ribose Polymerase 9 (PARP9):

A novel role of Poly ADP Ribose Polymerase 9 (PARP9) as a non-canonical RNA sensor suggests a potential for therapeutic interventions to control RNA virus infections.

Acetyl-CoA Synthetase 2 connects obesity and myeloma pathogenesis

Comprehensive detailed analyses using mouse models and cell lines identify acetyl CoA synthetase 2 as a pivotal player controlling the dynamic communication between adipocytes and myeloma cells during myeloma pathogenesis.

New Findings Offer Improved Therapy for Early-Stage, BRCA Mutation-Associated Breast Cancer

New treatment demonstrates it has the potential to improve the outcomes for patients with hereditary BRCA mutations

The Heart of Progress

Innovative valves continue DeBakey legacy for the future

Antibody to Fight Silent Killers

Joining forces to block MFAP5 protein in killer cancers

Revolutionizing Stroke Recovery

TRPMS cap reveals—and recovers—brain function

Strides in Dialysis Access

Eric Peden, MD, performs first minimally invasive surgery

Plasma Therapy Proves Transformative

First to offer clinical trial and publish a study, Houston Methodist sees happy outcome for COVID-19 patient

Antiviral May Offer New Treatment Option

New antiviral drug tested for COVID-19 patients

Trials Aim to Calm Cytokine Storms

Intensivist focuses on fighting dysregulated immune response

Safe Refuse for N95s

System Quality & Patient Safety teams develop autoclaving protocol

Remdesivir Proves Promising

Antiviral drug trial sees fast improvement for Houston Methodist patients

Sign up for Supplemental Methods - a quarterly newsletter from Methodology

Follow us

Copyright 2023. Houston Methodist, Houston, TX. All rights reserved.

Privacy & Disclaimer

Browse the Archive

Share this story